Agenus (NASDAQ: AGEN) has recently received a number of price target changes and ratings updates:
- 8/11/2026 – Agenus had its “buy” rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock, down from $30.00.
- 8/9/2026 – Agenus was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 8/7/2026 – Agenus was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
- 8/1/2026 – Agenus was upgraded by Wall Street Zen from “hold” to “buy”.
- 7/30/2026 – Agenus had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, up from $8.00.
- 7/18/2026 – Agenus was downgraded by Wall Street Zen from “buy” to “hold”.
- 7/13/2026 – Agenus had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a “buy” rating on the stock.
- 6/16/2026 – Agenus had its “sell (d)” rating reaffirmed by Weiss Ratings.
Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.
Featured Stories
- Five stocks we like better than Agenus
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
Receive News & Ratings for Agenus Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc and related companies with MarketBeat.com's FREE daily email newsletter.
